Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: A stable isotope kinetic study

European Journal of Clinical Investigation

Volumn 30, Issue 8, 2000, Pages 685-694

  Duvillard, L ^a   Pont, F ^b   Florentin, E ^a   Galland Jos, C ^b   Gambert, P ^b   Verges B ^b  

^a INSERM   (France)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Apolipoprotein B; Gas chromatography combustion isotope ratio mass spectrometry; Kinetic study; Non insulin dependent diabetes mellitus; Stable isotope

Indexed keywords

APOLIPOPROTEIN B; CARBON 13; INTERMEDIATE DENSITY LIPOPROTEIN; LEUCINE; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; KINETICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0033858450     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00755.x     Document Type: Article

References (61)

1. 1 Fontbonne A, Eschwége E, Cambien F, Richard JL, Ducimetière P, Thibult N et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 1989;32:300-4.
2. 2 Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H et al. Risk factors for myocardial infarction and death in newly detected NIDDM, the diabetes intervention study, 11-year follow-up. Diabetologia 1996;39:1577-83.
3. 3 Tkàc I, Kimball BP, Lewis G, Uffelman K, Steiner G. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 1997;17:3633-8.
4. 4 Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982;31:217-25.
5. 5 Taskinen MR, Beltz WF, Harper I, Fields RM, Schonfeld G, Grundy SM et al. Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Study before and after sulfonylurea therapy. Diabetes 1986;35:1268-77.
6. 6 Howard BV, Abbott WGH, Egusa G, Taskinen MR. Coordination of very-low-density lipoprotein triglyceride and apolipoprotein B metabolism in humans: effects of obesity and non-insulin-dependent diabetes mellitus. Am Heart J 1987;113:522-6.
7. 7 Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Naoumova R, Slavin BM et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 1995;38:959-67.
8. 8 Howard BV, Abbott WGH, Beltz WF, Harper IT, Fields RM, Grundy SM et al. Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetes. Metabolism 1987;36:870-7.
9. 9 Taskinen MR, Packard CJ, Sheperd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 1990;39:1017-27.
10. 10 Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus. J Clin Invest 1983;71:655-67.
11. 11 Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613-28.
12. 12 Taskinen MR, Harno K, Nikkila EA. Serum lipids and lipoproteins in type 2 diabetes. Acta Endocrinologica Supplement 1984;262:95-9.
13. 13 Schaefer JR, Rader DJ, Brewer HB. Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. Curr Op Lipidol 1992;3:227-32.
14. 14 Shames DM, Havel RJ. De novo production of low density lipoproteins: fact or fancy. J Lipid Res 1991;32:1099-112.
15. 15 Shen DC, Shien SM, Fuh MMT, Wu DA, Chen YDI, Reaven GM. Resistance to insulin-stimulated -glucose uptake in patients with hypertension. J Clin Endocr Metab 1988;66:580-3.
16. 16 Pont F, Duvillard L, Maugeais C, Athias A, Perségol L, Gambert P et al. Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics. Anal Biochem 1998;248:277-87.
17. 17 Pont F, Duvillard L, Vergès B, Gambert P. Development of compartmental models in stable isotope experiments: application to lipoprotein metabolism. Arterioscler Thromb Vasc Biol 1998;18:853-60.
18. 18 Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol 1992;262:E968-E975.
19. 19 Cobelli C, Toffolo G, Bier DM, Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am J Physiol 1987;253:E551-E564.
20. 20 Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS et al. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res 1995;36:1155-67.
21. 21 Maugeais C, Ouguerram K, Krempf M, Maugeais P, Gardette J, Bigot E et al. A minimal model using stable isotopes to study the metabolism of apolipoprotein B-containing lipoproteins in humans. Diabetes Metab 1996;22:57-63.
22. 22 Lagrost L, Athias A, Herbeth B, Guyard-Dangremont V, Artur Y, Paille F et al. Opposite effects of cholesteryl transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. J Biol Chem 1996;271:19058-65.
23. 23 Viens L, Athias A, Lizard G, Simard G, Gueldry S, Braschi S et al. Effect of lipid transfer activity and lipolysis on low density lipoprotein (LDL) oxidizability: evidence for lipolysis-generated non-esterified fatty acids as inhibitors of LDL oxidation. J Lipid Res 1996;37:2179-92.
24. 24 Havekes LM, de Knijff P, Biesigel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E pheno-typing directly in serum. J Lipid Res 1987;28:455-63.
25. 25 Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
26. 26 Vergès B, Rader D, Schaefer J, Zech L, Kindt M, Fairwell T et al. In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope kinetic study. J Lipid Res 1994;35:2280-91.
27. 27 Cummings MH, Watts GF, Pal C, Umpleby M, Hennessy TR, Naumova R et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin Sc 1995;88:225-33.
28. 28 Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius PH, Pugh WL et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is a important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Met 1991;72:934-44.
29. 29 Dashti N, Williams DL, Alaupovic P. Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in Hep G2 cells. J Lipid Res 1989;30:1365-73.
30. 30 Byrne CD, Brindle NP, Wang TW, Hales CN. Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. Biochem J 1991;280:99-104.
31. 31 Byrne CD, Wang TW, Hales CN. Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. Biochem J 1992;288:101-7.
32. 32 Dixon JL, Furukawa S, Ginsberg HN. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem 1991;266:5080-6.
33. 33 Benoist F, Grand-Perret T. Apo B-100 secretion by Hep G2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. Arterioscler Thromb Vasc Biol 1996;16:1229-35.
34. 34 Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes 1993;42:833-42.
35. 35 Lewis GF, Zinman B, Uffelman KD, Szeto LW, Weller B, Steiner G. VLDL production is decreased to a similar extent by acute portal vs peripheral venous insulin. Am J Physiol 1994;267:E566-E572.
36. 36 Malmström R, Packard CJ, Watson TDG, Rannikko S, Caslake M, Bedford D et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997;17:1454-64.
37. 37 Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158-66.
38. 38 Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H et al. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998;47:779-87.
39. 39 Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997;40:454-62.
40. 40 Pfeifer MA, Brunzell JD, Best JD, Judzewitsch RG, Halter JB, Porte DJ. The response of plasma triglyceride, cholesterol, and lipoprotein lipase to treatment in non-insulin-dependent diabetic subjects without familial hypertriglyceridemia. Diabetes 1983;32:525-31.
41. 41 Taskinen MR, Nikkila EA, Kuusi T, Harmo K. Lipoprotein lipase activity and serum lipoproteins in untreated type 2 (insulin-independent) diabetes associated with obesity. Diabetologia 1982;22:46-50.
42. 42 Appel B, Fried SK. Effects of insulin and dexamethasone on lipoprotein lipase in human adipose tissue. Am J Physiol 1992;262:E695-E699.
43. 43 Yki-Yarvinen H, Taskinen MR, Koivisto VA, Nikkila EA. Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in man. Diabetologia 1984;27:364-9.
44. 44 Egusa G, Beltz WF, Grundy SM, Howard BV. Influence of obesity on the metabolism of apolipoprotein B in humans. J Clin Invest 1985;76:596-603.
45. 45 Steinbrecher UP, Witztum JL. Glycosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984;33:130-4.
46. 46 Krämer-Guth A, Quaschning T, Galle J, Baumstark MW, Köninger M, Nauck M et al. Structural and compositional modifications of diabetic low-density lipoproteins influence their mediator-mediated uptake by hepatocytes. Eur J Clin Invest 1997;27:460-8.
47. 47 Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM. Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol 1996;16:794-801.
48. 48 Aviram M, Lund-Katz S, Phillips MC, Chait A. The influence of the triglyceride content of low density lipoprotein on the interaction of apolipoprotein B-100 with cells. J Biol Chem 1988;263:16842-8.
49. 49 Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes 1984;33:333-8.
50. 50 Wades DP, Knight BL, Soutar AK. Hormonal regulation of low-density lipoprotein (LDL) receptor activity in human hepatoma Hep G2 cells. Eur J Biochem 1988;174:213-18.
51. 51 Wades DP, Knight BL, Soutar AK. Regulation of low-density-lipoprotein-receptor mRNA by insulin in human hepatoma Hep G2 cells. Eur J Biochem 1989;181:727-31.
52. 52 Miller NE. Why does plasma low density lipoprotein concentration in adults increase with age ? Lancet 1984;1:263-7.
53. 53 Aguirre F, Martin I, Grinspon D, Ruiz M, Hager A, De Paoli T et al. Oxidative damage, plasma antioxidant capacity, and glycemic control in elderly NIDDM patients. Free Radic Biol Med 1998;24:580-5.
54. 54 Noberasco G, Odetti P, Boeri D, Maiello M, Adezati L. Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycosylated hemoglobin. Biomed Pharmacother 1991;45:193-6.
55. 55 Altomare E, Vendemiale G, Chicco D, Procacci V, Cirelli F. Increased lipid peroxydation in type 2 poorly controlled diabetic patients. Diabetes Metab 1992;18:264-71.
56. 56 Hunt JV. Glyco-oxidation of LDL. a biochemist's perspective. In: Colaco C, editor. The Glycation Hypothesis of Atherosclerosis. London: Bioscience, Austin; 1997.p. 109-126.
57. 57 Tribble DL, Holl LG, Wood PD, Krauss RM. Variation in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189-99.
58. 58 Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-6.
59. 59 Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994;5:395-403.
60. 60 Parthasarathy S, Quinn MT, Schwenke DC, Carew TE, Steinberg D. Oxidative modification of beta-very low density lipoprotein: potential role in monocyte recruitment and foam cell formation. Arteriosclerosis 1989;9:398-404.
61. 61 Whitman SC, Sawyez CG, Miller DB, Wolfe BM, Huff MW. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J Lipid Res 1998;39:1008-20.